Brittany Lovely is a managing editor for the OncologyLive® print publication and editor of the Miami Breast Cancer Conference® and Chemotherapy Foundation Symposium® dailies. Email: firstname.lastname@example.org
Trastuzumab Deruxtecan Undergoes Priority Review for HER2-Low Metastatic Breast Cancer
Based on data from the DESTINY-Breast04 trial, the FDA has granted a priority review designation for the supplemental biologics license application for fam-trastuzumab deruxtecan-nxki.
Early Treatment for Hot-Flashes Is Prognostic of Worse Outcomes for Hormonal Therapy in Patients with ER+ Breast Cancer
Patients with breast cancer who experience adjuvant hormone therapy (AHT)-related hot flashes and are treated for hot flashes at the beginning of therapy had worse outcomes than those who did not.
Tucatinib/Trastuzumab Combo Elicits Tumor Response in HER2+ mCRC
Data from the phase 2 MOUNTAINEER trial showed durable responses with tucatinib plus trastuzumab for patients with previously treated metastatic HER2-positive colorectal cancer.
Data Demonstrate Patient Uptake of Symptom Tracking With Digital Care Options
Engagement with patient-reported outcome assessments, digital education tools, and patient portal information highlighted disparities in care according to data from community practices.
Geriatric Assessment Rates Improve With Nurse Navigator Intervention
Nurse navigators may play a key role in mitigating toxicities from chemotherapy and perform geriatric assessments for patients treated at hematology/oncology clinics.
Luspatercept Linked With Maintained Reduction in Transfusion Dependence Among Patients With β-Thalassemia
Updated data from the phase 3 BELIEVE trial revealed a sustained reduction in the need for red blood cell transfusions among patients with β-thalassemia who received treatment with luspatercept-aamt.
Pediatric/Young Adult Patients With B-ALL Continue to Derive Benefit From Tisagenlecluecel at 5-Year Follow-Up
Heavily pretreated pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia maintained response with tisagenlecelucel according to long-term follow-up data from the phase 2 ELIANA trial.
All Patients With dMMR Rectal Cancer Experience Clinical Complete Response With Dostarlimab In Phase 2 Trial
At data cutoff, all treated patients in a phase 2 trial experienced a clinical complete response with single-agent dostarlimab-gxly.
Sacituzumab Govitecan Outperforms Chemotherapy in HR+/HER2- Metastatic Breast Cancer
Sacituzumab govitecan elicited a statistically significant and clinically meaningful benefit among patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
New Strategies Provide Faster Access To Cancer Care For Patients
Pilot programs based out of Yale Cancer Center and Moffitt Cancer Center seek to improve access for newly diagnosed patients with cancer.
Regardless of HER2 Expression, Responses Are Showcased With Sacituzumab Govitecan in TNBC
Sacituzumab govitecan-hziy significantly improved progression-free survival in patients with HER2-low expressing TNBC and HER2-negative disease.
Trastuzumab Deruxtecan Continues to Elicit Responses in HER2+ Breast Cancer With Active Brain Metastases
Patients with HER2-positive breast cancer who also have brain metastases experienced clinical benefit with fam-trastuzumab deruxtecan-nxki in the phase 2 TUEXEDO-trial.
E-Selectin Represents Promising Direction for AML Treatment Focus
Investigators are seeking to overcome barriers to help patients with acute myeloid leukemia achieve complete and durable remissions by focusing their attention on novel agents engineered to target adhesion factors.
Early Target Identification Will Help Maximize Osimertinib Treatment
Identifying targets early can help forestall resistance and improve the efficacy of osimertinib, a EGFR tyrosine kinase inhibitor, in the first-line setting.
Triplet Chemotherapy Combination a Viable Option for Colorectal Cancer Mutation
A combination of encorafenib (Braftovi), binimetinib (Mektovi), and cetuximab (Erbitux) in the first-line setting was tested for efficacy in patients with BRAF V600E–mutant CRC.
Get to the Root of Cancer Disparities
In order to achieve health equity for patients with cancer, physicians must first understand the root cause of heath disparities, many of which may be invisible. Broadening conversations about health and equity, drawing attention to gaps in care, and prompting urgency on the issues that influence health care are crucial first steps to turn conversation into action.
PIK3A-Mutant Breast Cancer Shows Increased Sensitivity to PI3Kα Inhibition
Patients with breast cancer who harbor multiple PIK3A-mutant tumors achieved a higher clinical benefit from PI3Kα inhibition compared with single mutant tumors according to response analysis data from the SANDPIPER trial.
Low-Intensity Surveillance Is Beneficial for High-Risk NMIBC
Low-intensity surveillance may be comparable to high-intensity surveillance for cancer control in patients with high-risk non-muscle invasive bladder cancer (NMIBC).
Sequencing Ovarian Cancer Treatments Remains Challenging
The future looks to be defined by essential clinical trials.
How to Double Clinical Trial Eligibility in Advanced Lung Cancer
Broader clinical trial criteria could nearly double the number of patients with advanced non-small cell lung cancer who are eligible to participate.
Olanzapine Significantly Reduces CINV in Patients Receiving MEC
Reimagining Frailty Screenings in Head and Neck Cancer
Screening for Pain and Depression is Not Enough in Cancer Care
Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPC
2 Clarke Drive Cranbury, NJ 08512